JPWO2022246459A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022246459A5 JPWO2022246459A5 JP2023571509A JP2023571509A JPWO2022246459A5 JP WO2022246459 A5 JPWO2022246459 A5 JP WO2022246459A5 JP 2023571509 A JP2023571509 A JP 2023571509A JP 2023571509 A JP2023571509 A JP 2023571509A JP WO2022246459 A5 JPWO2022246459 A5 JP WO2022246459A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- pharma
- tautomer
- stereoisomer
- foregoing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190766P | 2021-05-19 | 2021-05-19 | |
| US63/190,766 | 2021-05-19 | ||
| PCT/US2022/072452 WO2022246459A1 (en) | 2021-05-19 | 2022-05-19 | Combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024519845A JP2024519845A (ja) | 2024-05-21 |
| JPWO2022246459A5 true JPWO2022246459A5 (https=) | 2025-05-27 |
| JP2024519845A5 JP2024519845A5 (https=) | 2025-05-27 |
Family
ID=82492721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571509A Pending JP2024519845A (ja) | 2021-05-19 | 2022-05-19 | 併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240148733A1 (https=) |
| EP (1) | EP4340883A1 (https=) |
| JP (1) | JP2024519845A (https=) |
| CN (1) | CN117337193A (https=) |
| AR (1) | AR125921A1 (https=) |
| TW (1) | TW202313048A (https=) |
| WO (1) | WO2022246459A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3224341A1 (en) * | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AU2023349151A1 (en) | 2022-09-29 | 2025-04-03 | Insilico Medicine Ip Limited | Tead inhibitors and methods of uses thereof |
| WO2024176131A1 (en) * | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and kras g12d-inhibitor combinations for treating cancer |
| EP4688730A1 (en) * | 2023-03-27 | 2026-02-11 | Vivace Therapeutics, Inc. | Synthesis of a hippo-yap pathway modulator and a polymorph thereof |
| WO2025054190A1 (en) * | 2023-09-05 | 2025-03-13 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a yap/taz-tead inhibitor |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201992781A1 (ru) * | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| CA3073543A1 (en) * | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| HRP20230377T1 (hr) * | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| PT3735299T (pt) * | 2018-11-09 | 2024-11-25 | Hoffmann La Roche | Compostos de anéis fundidos |
| CA3118752A1 (en) * | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| HUE070525T2 (hu) * | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| CN114728905B (zh) * | 2019-11-13 | 2025-08-01 | 基因泰克公司 | 治疗性化合物及使用方法 |
| TW202128699A (zh) * | 2019-11-27 | 2021-08-01 | 美商建南德克公司 | 治療性化合物 |
| WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| EP4114830A1 (en) * | 2020-03-04 | 2023-01-11 | Genentech, Inc. | Heterobifunctional molecules as tead inhibitors |
| AU2021268094A1 (en) * | 2020-05-08 | 2022-10-27 | Cancer Research Technology Ltd. | Tricyclic heterocycles useful as TEAD binders |
| US11787775B2 (en) * | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
-
2022
- 2022-05-19 CN CN202280036206.2A patent/CN117337193A/zh active Pending
- 2022-05-19 JP JP2023571509A patent/JP2024519845A/ja active Pending
- 2022-05-19 TW TW111118775A patent/TW202313048A/zh unknown
- 2022-05-19 AR ARP220101338A patent/AR125921A1/es not_active Application Discontinuation
- 2022-05-19 WO PCT/US2022/072452 patent/WO2022246459A1/en not_active Ceased
- 2022-05-19 EP EP22741119.6A patent/EP4340883A1/en active Pending
-
2023
- 2023-11-15 US US18/510,227 patent/US20240148733A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492002B2 (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| JP2024023189A5 (https=) | ||
| RU2597844C2 (ru) | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака | |
| JP2024009951A5 (https=) | ||
| WO2006080327A1 (ja) | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 | |
| JP2010531304A5 (https=) | ||
| JP7611855B2 (ja) | ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩 | |
| JP2021524844A5 (https=) | ||
| CZ20032266A3 (cs) | Dávkovací formy pro ošetřování nádorů | |
| JPWO2022246459A5 (https=) | ||
| AU2007264665A1 (en) | Potentiator of radiation therapy | |
| JP5340393B2 (ja) | 腎細胞癌の治療のための３，３’，４，４’−テトラヒドロキシ−２，２’−ビピリジン−ｎ，ｎ’−ジオキシド | |
| JP3208437B2 (ja) | 癌転移抑制剤 | |
| EP2101790A1 (en) | Combination comprising cndac (2'-cyano-2'-deoxy-n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosine) and a cytotoxic agent | |
| JP6059224B2 (ja) | ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物 | |
| JP7669053B2 (ja) | ３－ケトアシルｃｏａタイオレース阻害剤とカルニチンアシルカルニチンキャリア阻害剤を含む癌の予防または治療のための医薬組成物 | |
| JP6895688B2 (ja) | 血液がんの新規治療法及び新規治療剤 | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia | |
| JP5103170B2 (ja) | ピリジン誘導体を有効成分とする放射線治療増強剤 | |
| CN105263499A (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| US20180021276A1 (en) | Bezafibrate for the treatment of cancer | |
| WO2025130826A1 (en) | Compositions and methods for treating cancer | |
| JP2842888B2 (ja) | リボヌクレアーゼインヒビターを有効成分とする癌細胞転移抑制剤 |